Clinical Trials Logo

Clinical Trial Summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.


Clinical Trial Description

Tranexamic acid (TXA) is an antifibrinolytic agent that acts to decrease bleeding by stabilizing the fibrin matrix involved in the clotting cascade. The use of TXA has been extensively described in the literature to prevent exsanguination in trauma and in various surgical procedures, as well as for heavy menstrual bleeding and epistaxis. Studies have suggested administration of TXA may improve outcomes in aesthetic surgery as well, specifically regarding intraoperative bleeding and postoperative ecchymosis and hematoma formation. TXA may be administered systemically, via IV or PO routes, or locally, via topical application or subcutaneous injection. Local administration allows for similar benefits with minimal risk of systemic effects. Following facial Mohs reconstruction patients often experience surgical site ecchymosis and swelling, which may be distressing, painful, prolong healing, and result in increased healthcare utilization. Other complications include hematoma, wound dehiscence, and suboptimal scarring. Given the growing body of literature demonstrating the benefits of TXA in surgical bleeding outcomes, TXA may also be beneficial in improving postoperative Mohs complications and patient satisfaction. To date, no studies have investigated the use of perioperative TXA specifically in nasal Mohs reconstruction. This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06057675
Study type Interventional
Source Vanderbilt University Medical Center
Contact Connie Ma, MD
Phone 2815366877
Email connie.ma@vumc.org
Status Recruiting
Phase Phase 2
Start date March 19, 2024
Completion date December 2024

See also
  Status Clinical Trial Phase
Completed NCT03199911 - Topical Antibiotic Prophylaxis for Eyelids Phase 4
Completed NCT04036344 - Buddy Relationships in DermatoloGic Excisions for Skin Cancer N/A
Completed NCT04336371 - Exploratory Prospective of Experienced by Patients in the Surgery of Skin Cancers of the Face in Interventional Dermatology Department
Not yet recruiting NCT06207786 - Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery N/A
Completed NCT04015453 - Correlation of Early Postoperative Scar Appearance With Long-term Scar Outcomes
Not yet recruiting NCT03382704 - Lanugo Hair Loss as a Marker for Peri-ocular Malignancy N/A